Study of Measles Vaccine Response in Children With Sickle Cell Disease Aged 6 Months to 6 Years

What this Trial Is About

This research aims to understand if infants and young children with sickle cell disease SCD develop adequate protection after receiving measles vaccines. It focuses on children aged between 6 months and 6 years who are eligible for measles vaccination as part of standard care. The study evaluates immune response specifically after the first and second doses of the measles vaccine without investigating long-term protection. Participants are divided into two groups one receiving their first measles vaccine MV1 and the other receiving their second measles vaccine MV2. Blood samples are collected before vaccination and then again at 4 and 8 weeks after vaccination to measure antibody response. The study tracks antibody development following each vaccine dose to assess vaccine immunogenicity in children with SCD. During the study, participants will have blood drawn at specified times and attend follow-up visits for sample collection and evaluations. Researchers will measure measles seroconversion rates at 4 and 8 weeks post-vaccination and analyze factors related to antibody responses. The study duration includes sample collection up to 8 weeks post-vaccination with additional analysis continuing up to 12 weeks. Families provide consent and participate in scheduled visits to support data collection.

Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease